Boehringer Ingelheim GmbH Release: AF Patients Who Require Surgery Benefit From a Shorter Treatment Interruption on Dabigatran Etexilate (Pradaxa®) Compared to Warfarin

INGELHEIM, Germany--(BUSINESS WIRE)--For Non-US, Non-UK & Non-Canadian Media Only: Findings published in Circulation demonstrate that Pradaxa® (dabigatran etexilate) is associated with a substantially shorter interruption of oral anticoagulation therapy compared to warfarin in patients with atrial fibrillation (AF)1 who require surgery, allowing patients to undergo procedures more quickly and reducing the time of reduced protection against stroke. Additionally, the study found that discontinuing Pradaxa® within 48 hours of surgery was associated with a lower risk of peri-operative bleeding compared to similar discontinuation times with warfarin.1

MORE ON THIS TOPIC